Zyrifa

Zydus Launches Zyrifa Denosumab Biosimilar for Bone Metastases Care

Zydus launches Zyrifa, a Denosumab biosimilar for patients with bone metastases, improving access to critical cancer care and supporting better mobility and treatment outcomes.